THE FIRST AND ONLY FDA APPROVED WAY TO ACCESS THE SUPRACHOROIDAL SPACE (SCS®)
Our SCS Microinjection Procedure is Clinically Proven for Targeted Delivery
Clearside’s proprietary SCS injection treatment approach offers unprecedented access to the back of the eye where sight-threatening disease often occurs.
Straightforward Suprachoroidal Injection Technique
Perpendicular
Hold the microinjector perpendicular to the ocular surface
Dimple
Ensure firm contact with sclera by maintaining a dimple throughout injection
Slow
Inject slowly over 5 – 10 seconds
Our SCS Microinjection Procedure
Clearside has developed the only clinically tested product to obtain FDA approval for suprachoroidal drug delivery. Suprachoroidal delivery enables the rapid dispersion of medicine to the back of the eye, offering the potential for the medicine to act longer and minimize harm to the surrounding healthy parts of the eye. Our proprietary SCS Microinjector® provides targeted delivery and is inherently flexible. It is designed to work with established medications, new formulations of medicines, as well as future innovations that can be delivered via suprachoroidal administration.
Clearside Needle Size Equivalent to Most Commonly Used Intravitreal Injections and Smaller than Other TKIs in development
Clearside has received the International Organization for Standardization (ISO) Certification EN ISO 13485:2016. The certificate can be accessed here.
References:
The SCS Microinjector has not been independently approved by the FDA; XIPERE® (triamcinolone acetonide injectable suspension) has been approved for suprachoroidal use with the SCS Microinjector.
Kurup, et. al, Macula Society 2021 Safety of the Suprachoroidal Injection Procedure Utilizing SCS Microinjector® across Three Retinal Disorders | Rai UDJ, Young SA, Thrimawithana TR, et al. The suprachoroidal pathway: a new drug delivery route to the back of the eye. Drug Discov Today. 2015;20(4):491-495. | Moisseiev E, Loewenstein A, Yiu G. The suprachoroidal space: from potential space to a space with potential. Clin Ophthalmol. 2016;10:173-178. | Chiang B, Jung JH, Prausnitz MR. The suprachoroidal space as a route of administration to the posterior segment of the eye. Adv Drug Deliv Rev. 2018;126:58-66. | Wykoff, et al, Retina, “Suprachoroidal Space Injection Technique Expert Panel Guidance”, 2024 | Yiu, Clinical Trials at the Summit, “Suprachoroidal Drug Delivery in the Real World”, 2024 | Villafuerte-Trisolini and Yiu, Retina Specialist, “A Beginner’s Guide to Suprachoroidal Injections” 2024 | Gustavo Barreto Melo, et al, Progress in Retinal and Eye Research. “Critical analysis of techniques and materials used in devices, syringes, and needles used for intravitreal injections”, https://doi.org/10.1016/j.preteyeres.2020.100862